Shopping Cart
- Remove All
Your shopping cart is currently empty
Semustine, a DNA alkylating agent, is a cancer chemotherapy compound that is nephrotoxic in patients with malignant melanoma receiving adjuvant chemotherapy for the adjuvant treatment of leukemia.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $67 | In Stock | |
| 5 mg | $162 | In Stock | |
| 10 mg | $240 | In Stock | |
| 25 mg | $411 | In Stock | |
| 50 mg | $575 | In Stock | |
| 100 mg | $803 | In Stock | |
| 200 mg | $1,080 | In Stock |
| Description | Semustine, a DNA alkylating agent, is a cancer chemotherapy compound that is nephrotoxic in patients with malignant melanoma receiving adjuvant chemotherapy for the adjuvant treatment of leukemia. |
| In vivo | Semustine (Me-CCNU) (150 mg×m(-2)×d(-1) once; oral; repeated every 28 days) treatment periods were within 2 - 6 months; follow-up period was 6 months. PFS at 6 months was 55.88% in the Me-CCNU group (P < 0.05). Overall survival rates at the end of the follow-up period were 97.30% in the Me-CCNU group (P > 0.05). Adverse events rates of Me-CCNU was 45.15% (P < 0.05).[2] |
| Molecular Weight | 247.72 |
| Formula | C10H18ClN3O2 |
| Cas No. | 13909-09-6 |
| Smiles | N(C(N(CCCl)N=O)=O)C1CCC(C)CC1 |
| Relative Density. | 1.31 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 45.0 mg/mL (181.7 mM), Sonication is recommended. DMSO: 90.0 mg/mL (363.3 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.